Minerva Neurosciences (NERV) Prepaid Assets (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Prepaid Assets came in at $941883.0 in Q1 2026, up 76.12% YoY from $534798.0 in Q1 2025, and up 35.0% on a QoQ basis from $697676.0 in Q4 2025.
Analysis
Minerva Neurosciences (NERV) Prepaid Assets (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Prepaid Assets data on file, last reported at $941883.0 in Q1 2026.
- Quarterly Prepaid Assets rose 76.12% year-over-year to $941883.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $941883.0 (up 76.12% YoY) and the FY2025 annual result came in at $697676.0, down 13.54% from the prior year.
- Prepaid Assets climbed to $941883.0 in Q1 2026, from $697676.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.4 million in Q3 2022 to a low of $184821.0 in Q2 2022.
- A 5-year average of $733855.5 and a median of $697676.0 in 2025 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets sank 79.7% — and 2023, when it jumped 78.09%.
- Tracing NERV's Prepaid Assets over 5 years: stood at $848117.0 in 2022, then increased by 16.71% to $989865.0 in 2023, then dropped by 18.48% to $806895.0 in 2024, then retreated by 13.54% to $697676.0 in 2025, then jumped by 35.0% to $941883.0 in 2026.
- The last three Prepaid Assets figures came in at $941883.0 (Q1 2026), $697676.0 (Q4 2025), and $633533.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.37 Mn |
| Mar 31, 2026 | 941,883.00 |
| Dec 31, 2025 | 697,676.00 |
| Sep 30, 2025 | 633,533.00 |
| Jun 30, 2025 | 199,615.00 |
| Mar 31, 2025 | 534,798.00 |
| Dec 31, 2024 | 806,895.00 |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 428,018.00 |
| Mar 31, 2024 | 702,546.00 |
| Dec 31, 2023 | 989,865.00 |
| Sep 30, 2023 | 1.22 Mn |
| Jun 30, 2023 | 329,153.00 |
| Mar 31, 2023 | 596,045.00 |
| Dec 31, 2022 | 848,117.00 |
| Sep 30, 2022 | 1.40 Mn |
| Jun 30, 2022 | 184,821.00 |
| Mar 31, 2022 | 650,481.00 |
| Dec 31, 2021 | 1.35 Mn |
| Sep 30, 2021 | 1.75 Mn |